GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow
Arexvy will launch in the US in time for the fall 2023 RSV season for adults 60 and older, GSK said. Pfizer’s Abrysvo is also pending at the FDA.
You may also be interested in...
Fostering a Culture of Innovation, From Evolutionary To Revolutionary
Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.
GSK’s RSV Vaccine Prospects In Youngest Pediatric Patients Looks Unlikely Per US FDA Label
Arexvy is the first vaccine approved for the respiratory virus, but GSK's RSV program may lose out on a key population due to safety concerns for individuals younger than two. For Arexvy, CDC’s advisory committee could limit recommendation to 65 and up at June meeting.